Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size

Yoshihiro Nishimura1,2, Maiko Taguchi1, Takafumi Nagai1, Masashi Fujihara1,2, Shigeru Honda2, Mamoru Uenishi11Department of Ophthalmology, Mitsubishi Kobe Hospital, Kobe, Japan; 2Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, JapanPurpose: To com...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fujihara M, Nagai T, Taguchi M, Nishimura Y, Honda S, Uenishi M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/005882f722334a328436f33943897a4c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:005882f722334a328436f33943897a4c
record_format	dspace
spelling	oai:doaj.org-article:005882f722334a328436f33943897a4c2021-12-02T03:45:12ZComparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size1177-54671177-5483https://doaj.org/article/005882f722334a328436f33943897a4c2012-03-01T00:00:00Zhttp://www.dovepress.com/comparison-of-the-effect-between-pegaptanib-and-ranibizumab-on-exudati-a9418https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Yoshihiro Nishimura1,2, Maiko Taguchi1, Takafumi Nagai1, Masashi Fujihara1,2, Shigeru Honda2, Mamoru Uenishi11Department of Ophthalmology, Mitsubishi Kobe Hospital, Kobe, Japan; 2Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, JapanPurpose: To compare the effect of pegaptanib versus ranibizumab on exudative age-related macular degeneration (AMD) with small lesion size.Methods: This is a retrospective study of 81 eyes from 78 patients with exudative AMD treated and followed up over 12 months. Patients with baseline best corrected visual acuity (BCVA) under 20/400 and with a greatest linear dimension of lesion over 4500 &micro;m were excluded from the study. Twenty-six eyes from 25 patients were treated with three consecutive intravitreal injections of pegaptanib (IVP group) and 55 eyes from 54 patients were treated with three consecutive ranibizumab injections (IVR group). Each therapy was repeated as needed. The alteration in BCVA was evaluated in the IVP and IVR groups.Results: No differences were detected in baseline parameters between the IVP and IVR groups. The mean BCVA (logMAR) at month 1, 3, 6 and 12 after the initial treatment was improved from baseline in the IVP group (-0.095, -0.17, -0.18 and -0.18, respectively) and in the IVR group (-0.077, -0.15, -0.17 and -0.11, respectively), which was statistically significant. There was no difference in the change in mean BCVA between IVP and IVR groups at the same time periods.Conclusions: The visual outcome of IVP was equivalent with IVR in exudative AMD with small lesion size.Keywords: pegaptanib, ranibizumab, age-related macular degeneration, small lesion sizeFujihara MNagai TTaguchi MNishimura YHonda SUenishi MDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 365-368 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Fujihara M Nagai T Taguchi M Nishimura Y Honda S Uenishi M Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size
description	Yoshihiro Nishimura1,2, Maiko Taguchi1, Takafumi Nagai1, Masashi Fujihara1,2, Shigeru Honda2, Mamoru Uenishi11Department of Ophthalmology, Mitsubishi Kobe Hospital, Kobe, Japan; 2Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, JapanPurpose: To compare the effect of pegaptanib versus ranibizumab on exudative age-related macular degeneration (AMD) with small lesion size.Methods: This is a retrospective study of 81 eyes from 78 patients with exudative AMD treated and followed up over 12 months. Patients with baseline best corrected visual acuity (BCVA) under 20/400 and with a greatest linear dimension of lesion over 4500 &micro;m were excluded from the study. Twenty-six eyes from 25 patients were treated with three consecutive intravitreal injections of pegaptanib (IVP group) and 55 eyes from 54 patients were treated with three consecutive ranibizumab injections (IVR group). Each therapy was repeated as needed. The alteration in BCVA was evaluated in the IVP and IVR groups.Results: No differences were detected in baseline parameters between the IVP and IVR groups. The mean BCVA (logMAR) at month 1, 3, 6 and 12 after the initial treatment was improved from baseline in the IVP group (-0.095, -0.17, -0.18 and -0.18, respectively) and in the IVR group (-0.077, -0.15, -0.17 and -0.11, respectively), which was statistically significant. There was no difference in the change in mean BCVA between IVP and IVR groups at the same time periods.Conclusions: The visual outcome of IVP was equivalent with IVR in exudative AMD with small lesion size.Keywords: pegaptanib, ranibizumab, age-related macular degeneration, small lesion size
format	article
author	Fujihara M Nagai T Taguchi M Nishimura Y Honda S Uenishi M
author_facet	Fujihara M Nagai T Taguchi M Nishimura Y Honda S Uenishi M
author_sort	Fujihara M
title	Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size
title_short	Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size
title_full	Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size
title_fullStr	Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size
title_full_unstemmed	Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size
title_sort	comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/005882f722334a328436f33943897a4c
work_keys_str_mv	AT fujiharam comparisonoftheeffectbetweenpegaptanibandranibizumabonexudativeagerelatedmaculardegenerationwithsmalllesionsize AT nagait comparisonoftheeffectbetweenpegaptanibandranibizumabonexudativeagerelatedmaculardegenerationwithsmalllesionsize AT taguchim comparisonoftheeffectbetweenpegaptanibandranibizumabonexudativeagerelatedmaculardegenerationwithsmalllesionsize AT nishimuray comparisonoftheeffectbetweenpegaptanibandranibizumabonexudativeagerelatedmaculardegenerationwithsmalllesionsize AT hondas comparisonoftheeffectbetweenpegaptanibandranibizumabonexudativeagerelatedmaculardegenerationwithsmalllesionsize AT uenishim comparisonoftheeffectbetweenpegaptanibandranibizumabonexudativeagerelatedmaculardegenerationwithsmalllesionsize
_version_	1718401622445391872

Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size

Ejemplares similares